美股A股
StockGist
Back
8-K2026-05-07· qwen-plus

PRKR · ParkerVision, Inc.

0001437749-26-015571

SEC filing

Summary

ParkerVision reported a reduced net loss of $1.6 million for Q1 2026 versus $3.8 million in Q1 2025, driven by a $2.1 million favorable change in fair value of contingent payment obligations; cash balance declined to $3.4 million, and key patent litigation timelines were delayed amid judicial transitions in the Western District of Texas.

Key takeaways

Full analysis

ParkerVision’s Q1 2026 financial results reflect a significant reduction in net loss—$1.6 million versus $3.8 million in the prior-year quarter—driven almost entirely by a $2.1 million favorable change in the estimated fair value of its contingent payment obligations, which are tied to future patent enforcement proceeds. This non-cash adjustment dominates the income statement: licensing revenue remained zero, gross margin was negative $36,000 (due to cost of sales), and SG&A expenses declined modestly to $958,000 from $1.2 million. The company used $0.9 million in operating cash, ending the quarter with $3.4 million in cash—down $937,000 from December 31, 2025—underscoring continued reliance on litigation outcomes for liquidity. Legally, the most consequential development is the CAFC’s expedited schedule for the Qualcomm appeal, with oral arguments set for June 1, 2026; this case, now over twelve years old, centers on claim construction that led to a stipulation of noninfringement for receiver patents, while transmitter claims remain stayed. Simultaneously, both the MediaTek and Realtek trials in Texas were postponed after Judge Albright vacated all pending dates on April 24, 2026, citing his upcoming departure from the bench. The court directed ParkerVision to revise expert reports by May 8, 2026, introducing uncertainty around trial timing and reinforcing dependence on judicial continuity and expert testimony quality. Management acknowledged disappointment but framed the delay as an opportunity to strengthen evidentiary submissions—though no new trial dates have been set, and no forward-looking guidance was provided beyond commentary on appellate progress.